Autolus Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $10.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gil Blum’s rating is based on several positive developments for Autolus Therapeutics. The recent conditional EU approval of Aucatzyl (obe-cel) for adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is a significant milestone. This decision follows strong efficacy and safety data from the pivotal FELIX study and a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) earlier in the year.
Additionally, Aucatzyl has already received conditional approval in the U.K., with a launch expected soon. The early demand in the U.S. market, evidenced by $9 million in sales for the first quarter of 2025, further supports the positive outlook. These factors, combined with the estimated sales growth, underpin the Buy rating and a price target of $10.
According to TipRanks, Blum is an analyst with an average return of -7.9% and a 37.35% success rate. Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Sarepta Therapeutics, and Autolus Therapeutics.